Long-term efficacy of spironolactone on pain, mood, and quality of life in women with fibromyalgia: an observational case series http://www.scandinavianjournalpain.com/article/S1877-8860(14)00006-8/abstract (Full text is behind a paywall.) There are other discussions of spironolactone here: http://forums.phoenixrising.me/inde...ed-seem-to-be-helping-me-spironolactone.5166/ and post #23 here: http://forums.phoenixrising.me/inde...ne-system-be-harmful.13013/page-2#post-219624 Begin Journal Article Highlights •Spironolactone as add-on medication improved symptoms in women with treatment-resistant fibromyalgia syndrome. •Fifteen of 31 women responded to spironolactone and were observed for 12–14 months. •Spironolactone improved pain, stiffness, fatigue, anxiety, depression, and mood. •Beneficial effects were obvious at 4–6 weeks and persisted over the whole observation period. Abstract Objective No single drug is broadly efficacious in the long-term treatment of fibromyalgia syndrome (FMS). Spironolactone is known to ameliorate mood and tension headache or migraine in women with premenstrual syndrome or clinical signs of hyperandrogenism. In a case series of women with treatment resistant FMS spironolactone was therefore added to their medication, and they were observed for at least 12 months. Methods 31 women with treatment-resistant FMS received spironolactone as add-on medication to various pain modulating drugs. 15 women responded to spironolactone and baseline data were compared with assessments over 12–14 months on treatment with spironolactone (ALDACTONE®) in dose range 100–200mg/day. The efficacy was evaluated by the fibromyalgia impact questionnaire (FIQ) total score and 8 FIQ subtests, a German mood inventory (BSKE-EWL), and further assessments of changes in relevant psychological and physical complaints. 16 women had no effect and stopped the treatment early. Results The subsequent data refer to the 15 responders. The FIQ total score (maximal score=80) decreased from 56.6±10.0 at baseline to 17.1±11.9 (mean±SD) 12–14 months later, and pain intensity on an 11 point numeric rating scale (NRS) decreased from 8.8±1.6 to 2.6±1.9 (mean±SD). Similar changes in FIQ subscores were found for fatigue, morning tiredness, stiffness, anxiety, and depression. Regular monitoring of serum potassium did not reveal hyperkalemia. All 15 women were able to reduce or discontinue concomitant drugs.